Mobius Therapeutics, LLC Sustainability Profile
Mobius Therapeutics, LLC, headquartered in the United States, is a pioneering company in the pharmaceutical industry, specialising in innovative ophthalmic solutions. Founded in 2013, Mobius has made significant strides in developing unique products that enhance patient care in the field of eye health. The company is renowned for its flagship product, Mitosol, a proprietary formulation of mitomycin-C, which is specifically designed for use in glaucoma and cataract surgeries. This product stands out due to its advanced delivery system, ensuring precise application and improved outcomes for patients. With a strong market position, Mobius Therapeutics has garnered recognition for its commitment to quality and innovation, making it a trusted name among healthcare professionals. The company continues to expand its operational reach, focusing on enhancing surgical techniques and patient safety in ophthalmology.
DitchCarbon Score
How does Mobius Therapeutics, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mobius Therapeutics, LLC's score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mobius Therapeutics, LLC's reported carbon emissions
Mobius Therapeutics, LLC, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Mobius Therapeutics may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the industry increasingly prioritises climate action, it will be essential for Mobius Therapeutics to consider developing and communicating its environmental strategies to align with broader corporate responsibility trends.
How Carbon Intensive is Mobius Therapeutics, LLC's Industry?
How Carbon Intensive is Mobius Therapeutics, LLC's Location?
Mobius Therapeutics, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mobius Therapeutics, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
